stockrowTransMedics Group, Inc.
TMDX Healthcare Medical Devices
TransMedics Group, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $605.5 million, up 37.1% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −31.0%
- Free cash flow
- −55.4%
- Total debt
- −89.3%
Quarter to September 2026, against a year earlier
Follow TMDX
Alert me
TransMedics Group, Inc. (TMDX) Return on assets
TransMedics Group, Inc.'s return on assets over the twelve months to 30 September 2026 was 11.7%, down 8.6 percentage points from fiscal 2025 (20.3%). Over the past ten years it has ranged from −112.7% (fiscal 2018) to 20.3% (fiscal 2025) — the current reading is the highest in ten years. That is above the Medical Devices industry median of −17.3% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 20.3% | 15.63 |
| FY2024 | 4.70% | 9.79 |
| FY2023 | −5.09% | 12.50 |
| FY2022 | −17.6% | 13.23 |
| FY2021 | −30.8% | (8.48) |
| FY2020 | −22.3% | 23.16 |
| FY2019 | −45.5% | 67.20 |
| FY2018 | −112.7% | (60.09) |
| FY2017 | −52.6% | (52.61) |
| FY2016 | 0.00% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| TMDX TransMedics Group, Inc. | 11.7% |
| UFPT UFP Technologies, Inc. compare | 11.5% |
| INSP Inspire Medical Systems, Inc. compare | 11.4% |
| NEOG Neogen Corporation compare | −1.68% |
| AXGN AxoGen, Inc. compare | −8.33% |
| NVCR NovoCure Limited compare | −11.1% |
| ESTA Establishment Labs Holdings Inc. compare | −11.4% |
| BFLY Butterfly Network, Inc. compare | −18.6% |
| ALMR Alamar Biosciences, Inc. compare | −20.8% |
| Medical Devices industry median | −17.3% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on TMDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement